Similar articles

• [Symposium: metabolism in neurological disorders. 1. Parkinsonism. 1-(2). Dopamin metabolism in urine and brain of patients with parkinsonism, with special reference to vitamin B 6 and L-DOPA-treatment].

  Kuzuya F, Wakita T, Kawahara H. Kuzuya F, et al. Nihon Naika Gakkai Zasshi. 1972 Sep;61(9):1131-5. Nihon Naika Gakkai Zasshi. 1972. PMID: 4674039 Japanese. No abstract available.
• The metabolism of orally administered L-dopa in Parkinson patients.

  Cote LJ, Cohen G, Yahr MD. Cote LJ, et al. Trans Am Neurol Assoc. 1971;96:222-3. Trans Am Neurol Assoc. 1971. PMID: 5159086 No abstract available.
• [The therapeutic use of L-DOPA in Parkinson's disease. Biochemical, pharmacological and clinical considerations].

  Morselli PL, Rizzo M, Tognoni G. Morselli PL, et al. Recenti Prog Med. 1970 Feb;48(2):97-124. Recenti Prog Med. 1970. PMID: 5467589 Italian. No abstract available.
• L-dopa, behavioral activation and psychopathology.

  Murphy DL. Murphy DL. Res Publ Assoc Res Nerv Ment Dis. 1972;50:472-93. Res Publ Assoc Res Nerv Ment Dis. 1972. PMID: 4627219 Review. No abstract available.
• [Biochemical bases for the treatment of Parkinson's syndrome with L-dopa].

  Pletscher A, Bartholini G, Gey KF, Jenni A. Pletscher A, et al. Schweiz Med Wochenschr. 1970 May 9;100(19):797-804. Schweiz Med Wochenschr. 1970. PMID: 4924275 Review. German. No abstract available.